Oncobiologics announced a collaboration agreement with XOMA Corporation to develop novel biotherapeutics based on engineering single-chain variable fragments into a bi-specific antibody scaffold. Through the partnership, Oncobiologics will utilize XOMA's ADAPT fully human antibody technology platform as a key component of its drug discovery program. Under the agreement, Oncobiologics will gain access to XOMA's highly diverse library of scFv antibodies and associated patent estate, and will utilize XOMA's know-how and proven software tools as it advances its own candidates for treating cancer and immune diseases. Financial terms were not disclosed.
America has no tolerance for wealthy people griping about their financial woes. But they have concerns too.